Optimal methods for generating expanded lymphokine activated killer cells capable of reducing established murine tumors in vivo
- 12 November 1986
- journal article
- research article
- Published by Elsevier in Journal of Immunological Methods
- Vol. 94 (1-2), 37-49
- https://doi.org/10.1016/0022-1759(86)90213-9
Abstract
No abstract availableKeywords
This publication has 20 references indexed in Scilit:
- Observations on the Systemic Administration of Autologous Lymphokine-Activated Killer Cells and Recombinant Interleukin-2 to Patients with Metastatic CancerNew England Journal of Medicine, 1985
- Recombinant interleukin 2 stimulates in vivo proliferation of adoptively transferred lymphokine-activated killer (LAK) cells.The Journal of Immunology, 1985
- Lymphokine-activated killer (LAK) cells. Analysis of factors relevant to the immunotherapy of human cancerCancer, 1985
- Adoptive Immunotherapy of Established Pulmonary Metastases with LAK Cells and Recombinant Interleukin-2Science, 1984
- Biological Activity of Recombinant Human Interleukin-2 Produced in Escherichia coliScience, 1984
- Successful immunotherapy of natural killer-resistant established pulmonary melanoma metastases by the intravenous adoptive transfer of syngeneic lymphocytes activated in vitro by interleukin 2.The Journal of Experimental Medicine, 1984
- Structure and expression of a cloned cDNA for human interleukin-2Nature, 1983
- A simplified method for the production of murine T-cell growth factor free of lectinJournal of Immunological Methods, 1981
- Passive Immunotherapy of Cancer in Animals and ManAdvances in Cancer Research, 1977
- A generalized Wilcoxon test for comparing arbitrarily singly-censored samplesBiometrika, 1965